1. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med
1993;328:673-9.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. Randomized study with the sirolimus-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
3. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41:233-43.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996:335:1001-9.
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med
1998;339:1349-57.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
7. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention:
Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54:558-65.
8. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ.
Death following creatine kinase-MB elevation after coronary intervention: Identification of an early risk period: Importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002;106:1205-10.
9. Kodama Y, Kitta Y, Nakamura T, Takano H, Umetani K, Fujioka D, et al. Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute mvocardial infarction. J Am Coll Cardiol
2006;48:43-50.
10. Sakata K, Mochizuki M, Yoshida H, Nawada R, Ohbayashi K.
Ishikawa J, et al. Cardiac sympathetic dysfunction contributes to left ventricular remodeling after acute myocardial infarction. Eur J Nucl Med 2000:27:1641-9.
11. Matsunari I, Schricke U, Bengel FM, Haase HU, Barthel P, Schmidt G, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000;101:2579-85.
12. Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y,
Minami K, et al. Prognostic value of cardiac sympathetic nerve activity evaluated by [1231]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction. Heart
2011;97:20-6.
13. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine- 123-MIBG release in heart fail-ure. J Nucl Med 1997;38:1085-9.
14. Toyama T, Hoshizaki H, Seki R, Isobe N, Adachi H, Naito S, et al.
Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopa-thy: Comparison with metoprolol therapy. J Nucl Med
2003;44:1604-11.
15. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:574-81.
16. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol
2005;45:661-7.
17. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2007;49:667-74.
18. Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y,
Minami K, et al. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. Int J Cardiol
2013;167:244-9.
19. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure.
Circulation 2003;107:2493-8.
20. Lee TM, Lin MS, Chang NC. Effect of pravastatin on sympathetic reinnervation in postinfarcted rats. Am J Physiol Heart Circ Physiol 2007;293:H3617-26.
21. Kang CS, Chen CC, Lin CC, Chang NC, Lee TM. Effect of ATP-sensitive potassium channel agonists on sympathetic hyperinner-vation in postinfarcted rat hearts. Am J Physiol Heart Circ Physiol
2009;296:H1949-59.
22. Jacobson AF, White S, Travin MI, Tseng C. Impact of concomitant medication use on myocardial 123I-mIBG imaging results in patients with heart failure. Nucl Med Commun 2017:38:141-8.
23. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blu-menthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC/LA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation
2019;139: 1046-81.
24. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R,
Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Ouantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
25. Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. J Nucl Med 2007;48:1676-82.
26. Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y,
Minami K, et al. Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. Heart 2011;97:817-22.
27. Luellen JK, Shadish WR, Clark MH. Propensity scores: An introduction and experimental test. Eval Rev 2005;29:530-58.
28. Mann DL. Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res 2002;91:988-98.
29. Lefer DJ. Statins as potent antinflammatory drugs. Circulation
2002;106:2041-2.
30. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, et al. Left ventricular remodeling after primary coronary angioplasty: Patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002;106:2351-7.
31. Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: Adrenomedullary imaging with [131I]iodobenzylguani-dine. J Nucl Med 1980;21:349-53.
32. Burgdorf C, Dendorfer A, Kurz T, Schömig E, Stölting I, Schütte F, et al. Role of neuronal KATP channels and extraneuronal monoamine transporter on norepinephrine overflow in a model of myocardial low flow ischemia. J Pharmacol Exp Ther
2004;309:42-8.
33. Lardizabal JA, Deedwania PC. The anti-ischemic and anti-anginal properties of statins. Curr Atheroscler Rep 2011;13:43-50.
34. Aikawa T, Naya M, Obara M, Oyama-Manabe N, Manabe O, et al.
Regional interaction between myocardial sympathetic enervation, contractile dysfunction, and fibrosis in heart failure with preserved ejection fraction: 11C-hydroxyephedrine PET study. Eur J Nucl Med Mol Imaging 2017;44:1897-905.
35. Kramer CM, Nicol PD, Rogers WJ, Suzuki MM, Shaffer A, Theobald TM, et al. Reduced sympathetic innervation underlies adjacent noninfarcted region dysfunction during left ventricular remodeling. J Am Coll Cardiol 1997;30(4): 1079-85.
36. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch
K, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J.Cardiol 1995;75:913-8.
37. Host NB, Jensen LT, Bendixen PM, Jensen SE, Koldkjaer OG, Simonsen EB. The aminoterminal propeptide of type III procol-lagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol 1995;76:869-73.
38. Tamaki N, Kuge Y, Yoshinaga K. Molecular imaging in heart failure patients. Clin Trans Imaging 2013;1:341-51.